Chest ACCP Career Connection
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (12)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chin, K. M.
Right arrow Articles by Rubin, L. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chin, K. M.
Right arrow Articles by Rubin, L. J.
(Chest. 2006;130:1657-1663.)
© 2006 American College of Chest Physicians

Is Methamphetamine Use Associated With Idiopathic Pulmonary Arterial Hypertension?

Kelly M. Chin, MD; Richard N. Channick, MD, FCCP and Lewis J. Rubin, MD, FCCP

* From the Department of Internal Medicine (Dr. Chin), Division of Pulmonary and Critical Care Medicine, St. Paul University Hospital, Dallas, TX; and Department of Internal Medicine (Drs. Channick and Rubin), Division of Pulmonary and Critical Care Medicine, University of California, San Diego, San Diego, CA.

Correspondence to: Richard Channick, MD, 9330 Campus Point Dr, MC 7381, La Jolla, CA 92037; e-mail: rchannick{at}ucsd.edu

Abstract

Background: Amphetamine, methamphetamine, and cocaine are suspected of being pulmonary hypertension risk factors based on a small number of case reports along with pharmacologic similarities to fenfluramine, a diet drug associated with pulmonary arterial hypertension (PAH). We sought to determine whether rates of stimulant use are increased in patients believed to have idiopathic PAH compared with patients with PAH and known risk factors and patients with chronic thromboembolic pulmonary hypertension (CTEPH).

Methods: In this retrospective study, rates of stimulant use were determined for 340 patients with idiopathic PAH, PAH and known risk factors, or CTEPH seen between November 2002 and April 2004. "Stimulant" use was defined as any reported use of amphetamine, methamphetamine, or cocaine. Odds of stimulant use were calculated using a polychotomous logistic regression model.

Results: A history of stimulant use was found in 28.9% of patients with a diagnosis of idiopathic PAH, compared with 3.8% of patients with PAH and a known risk factor, and 4.3% of patients with CTEPH. After adjustment for differences in age, patients with idiopathic PAH were 10.14 times (95% confidence interval, 3.39 to 30.3; p < 0.0001) more likely to have used stimulants than patients with PAH and known risk factors, and 7.63 times (95% confidence interval, 2.99 to 19.5; p < 0.0001) more likely to have used stimulants than patients with CTEPH.

Conclusions: Patients with idiopathic PAH are significantly more likely to have used stimulants than patients with other forms of pulmonary hypertension.

Key Words: illicit drugs • methamphetamine • pulmonary hypertension • risk factors




This article has been cited by other articles:


Home page
ChestHome page
R. B. Rothman and M. H. Baumann
Methamphetamine and Idiopathic Pulmonary Arterial Hypertension: Role of the Serotonin Transporter
Chest, October 1, 2007; 132(4): 1412 - 1413.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American College of Chest Physicians.